ALSO NOTED: PDI loses big sales contract; Bio Stem acquires Cryobanks; New CEOs at Gene Logic, Chemokine; and much more...

> Shares of PDI slid after the company announced that it is losing a $35 million sales contract. Release

> Bio Stem is acquiring Cryobanks International, obtaining nearly 9,000 internationally registered cord blood stem cell units being inventoried at their Altamore Springs, FL location. Release 

> Chutes & Ladders: Gene Logic has tapped Charles L. Dimmler III to serve as president and chief executive; Richard Piazza has been named the new CEO at Chemokine. Report

> AstraZeneca has opened a $15 million process and development lab in Bangalore, India. Report

> Some powerful lawmakers have called on Amgen to halt all physician incentives related to its anemia drugs, Epogen and Aranesp, until an FDA committee has a chance to evaluate safety concerns. Report

> AEterna Zentaris announced that a clinical trial of its prostate drug cetrorelix demonstrated it was safe and well tolerated in Phase IIa. A Phase IIb for efficacy is being planned. Report

> Vion Pharmaceuticals has extended its manufacturing agreement with SAFC, a member of the Sigma-Aldrich Group, for its lead anticancer agent Cloretazine to September 2009. Report

And Finally... Eli Lilly is donating $50 million to help stamp out a highly virulent form of TB. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.